Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | CES1 | P23141 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7734068 | 0.88 | TAAR1 (0.67) | LOXL2CES1CYP1A2CYP2D6CYP2C9 | |
| Benzylamine SCHEMBL2841170 | 0.84 | LOXL2 (0.78) | LOXL2CES1CYP1A2CYP2D6CYP2C9 | |
| Benzylamine SCHEMBL2841167 | 0.84 | LOXL2 (0.78) | LOXL2CES1CYP1A2CYP2D6CYP2C9 | |
| Phenethylamine SCHEMBL20239925 | 0.83 | TAAR1 (0.64) | LOXL2CES1SMN1; SMN2HIF1ACPA1 | |
| Trifluoroacetic Acid SCHEMBL30182273 | 0.83 | LOXL2 (0.60) | LOXL2CYP1A2CYP2D6CYP2C9TSHR | |
| Trifluoroacetic Acid SCHEMBL28713743 | 0.83 | LOXL2 (0.64) | LOXL2SMN1; SMN2TAAR1ITGB3ITGB1 | |
| Benzylamine SCHEMBL27825396 | 0.83 | LOXL2 (0.61) | LOXL2CES1CYP1A2CYP2D6CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL7850280 | 0.82 | ALDH1A1 (0.48) | LOXL2CYP1A2CYP2C19SMN1; SMN2TAAR1 | |
| Aminomethylbenzoic Acid SCHEMBL7422142 | 0.82 | ALDH1A1 (0.50) | LOXL2CYP1A2TSHRITGB3ITGB1 | |
| Trifluoroacetic Acid SCHEMBL18587850 | 0.82 | ITGB3 (0.44) | LOXL2SMN1; SMN2ITGB3ITGB1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333641-B | Enhanced fluorescent probe for tetrazine bio-orthogonal labeling and synthesis thereof | 中国科学院大连化学物理研究所 | 2022-05-31 | — | — | CN | claimed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | claimed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | claimed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | claimed |
| EP-2864308-A1 | COMPOUND AND METHOD | University Of Bristol (GB) | 2015-04-29 | — | — | EP | claimed |
| WO-2013186550-A1 | COMPOUND AND METHOD | UNIVERSITY OF BRISTOL (GB) | 2013-12-19 | — | — | WO | claimed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | claimed |
| EP-4568951-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024035627-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| EP-4161578-A1 | THERAPEUTIC CONJUGATES | Starpharma Pty Limited (AU) | 2023-04-12 | — | — | EP | disclosed |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-04-14 | — | — | US | disclosed |
| EP-1222172-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | Bristol-Myers Squibb Pharma Company (US) | 2002-07-17 | — | — | EP | disclosed |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-09 | — | — | US | disclosed |
| WO-2002022845-A1 | PROCESS FOR PREPARING N-SUBSTITUTED 4-HYDROXYPIPERIDINES BY ENZYMATIC HYDROXYLATION | Eidgenössische Technische Hochschule Zürich (CH) | 2002-03-21 | — | — | WO | disclosed |
| EP-1188837-A1 | Process for preparing N-substituted 4-hydroxypiperidines by enzymatic hydroxylation | Eidgenössische Technische Hochschule Zürich (CH) | 2002-03-20 | — | — | EP | disclosed |
| US-6329527-B1 | ACYLATING SUBSTITUTEDARYL HYDRAZINE, FORMING DIPOLAR COMPOUND, CONTACTING DIPOLAROPHILE AND SUBJECTING TO OXIDATION, REMOVING PROTECTING GROUP | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-12-11 | — | — | US | disclosed |
| WO-2001029006-A1 | SYNTHESIS OF 1,3,5-TRISUBSTITUTED PYRAZOLES AND INTERMEDIATES THEREFORE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-04-26 | — | — | WO | disclosed |
| CN-1190395-A | Substituted (sulfonic, sulfinic, sulfonamido or sulfonamido) N- [ aminoiminomethyl) phenylalkyl ] -azaheterocyclic amide compounds | RHONE POULENC RORER PHARMA (US) | 1998-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116892-A1 | HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS | JAK2, JAK1, JAK3 | LOXL2 3516/4885CES1 3621/4885CYP1A2 4251/4885 |
| US-20020055641-A1 | Synthesis of 1,3,5-trisubstituted pyrazoles | TFPI, SERPINC1, F11 | LOXL2 2647/4885CES1 161/4885CYP1A2 114/4885 |
| US-10618884-B2 | Deuterated diaminopyrimidine compounds and pharmaceutical compositions comprising such compounds | DCK, DPYD, BRAF | LOXL2 4310/4885CES1 4179/4885CYP1A2 3036/4885 |
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | LOXL2 1954/4885CES1 544/4885CYP1A2 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.